San Diego-based mostly Viking Therapeutics marked alone as a significant competitor inside the weight loss drug current market in February after revealing promising information from a mid-stage trial of experimental drug VK2735, which advised it rivaled—and outperformed—Novo and Lilly drugs when presented as being a weekly injection As well as